Generic heart medication shown to prolong ovarian cancer patients' survival

August 24, 2015, University of Texas M. D. Anderson Cancer Center
Intermediate magnification micrograph of a low malignant potential (LMP) mucinous ovarian tumour. H&E stain. The micrograph shows: Simple mucinous epithelium (right) and mucinous epithelium that pseudo-stratifies (left - diagnostic of a LMP tumour). Epithelium in a frond-like architecture is seen at the top of image. Credit: Nephron /Wikipedia. CC BY-SA 3.0

In a first-of-its-kind study, researchers demonstrate a benefit in overall survival among epithelial ovarian cancer (EOC) patients receiving generic heart medications known as beta-blockers. Survival was shown to be greatest among those prescribed first-generation nonselective beta-blockers. According to The University of Texas MD Anderson Cancer Center investigators, the drugs block the effects of stress pathways involved in tumor growth and spread. With further research, they may also prove beneficial in conjunction with other treatment regimens and across other cancer types.

Published today in the journal Cancer, the findings are the result of a multi-institutional retrospective analysis of the medical records of 1,425 women with treated between 2000 and 2010. Researchers compared overall survival among patients with documented beta-blocker use during chemotherapy and those without. Among the 269 patients who received beta-blockers, 193 (71.7 percent) received beta-1-adrenergic receptor selective agents (SBBs) and the remaining patients received nonselective beta antagonists (NSBBs). The research team found:

  • For patients receiving any beta-blocker, the median overall survival was 47.8 months versus 42 months for nonusers.
  • Median overall survival based on beta-blocker receptor selectivity was 94.9 months for those receiving NSBBs versus 38 months for those receiving SBBs.
  • Even among patients with hypertension, a longer median overall survival was observed among users of NSBBs compared with nonusers (90 months versus 38.2 months).

This study builds on a large body of research by principal investigator Anil Sood, M.D., professor in Gynecologic Medical Oncology and Cancer Biology at MD Anderson. It showed that stress hormones fuel progression of ovarian and other cancers, and that beta-blockers - among the most proven drugs in cardiovascular medicine - might be a new way to stifle that effect.

"Beta-blockers treat a variety of conditions, such as heart disease, high-blood pressure, glaucoma and migraines. They target a receptor protein in heart muscle that causes the heart to beat harder and faster when activated by stress hormones," Sood said. "Our research has shown that the same stress mechanisms impact ovarian progression, so these drugs could play a new role in cancer treatment."

According to Sood, the usefulness of beta-blockers was unclear until now. "The ability to show improved survival using nonselective agents - which inhibit a specific stress pathway - is the culmination of years of research into ovarian and pathogenesis."

He added that beta-blocker users in the study presented at a higher stage of disease, had an increased average BMI and were more likely to be hypertensive. All these factors were associated with decreased survival, yet those who received beta-blockers had either equivalent or improved overall survival. Further examination revealed that NSBB users had improved overall survival regardless of the presence of such prognostic factors or comorbidities. This was not true for patients who took SBBs.

Although further study is needed, these results highlight the importance of adrenergic receptor-β2 (ADRB2), a signaling pathway important to ovarian carcinogenesis and targeted by NSBBs (versus the ADRB1 pathway targeted by SBBs).

Ovarian cancer is the 5th most deadly cancer among women, accounting for more deaths than any other female reproductive system cancer. An estimated 21,290 new cases are diagnosed, and some 14,180 women die from the disease each year in the U.S., according to the American Cancer Society.

Future trials will seek to identify patients who would benefit most from beta-blocker use and the best beta-blocker for a specific tumor type based on adrenergic receptor expression. Then they potentially could be used as an adjuvant therapy during surgical recovery and chemotherapy to decrease tumor growth, delays in wound healing and metastasis. Beta-blockers may also reduce cancer-related psychological distress in newly diagnosed patients, according to the study authors.

There are currently two clinical trials, one led by MD Anderson, evaluating the combination of chemotherapy and propranolol (a type of NSBB) on cancer biology and on stress modulators in patients with newly diagnosed EOC. According to Sood, the preliminary data from these feasibility trials will be used to design prospective, randomized clinical trials examining NSBBs on patient outcomes.

"The stratification of patients by beta-blocker use and selectivity in this study makes it unique among all other studies examining the impact of these drugs on cancer. It also builds on the mounting evidence that beta-blockers may become a key treatment component for many in the future," said Sood.

Explore further: Lung cancer patients live longer if they use beta-blockers while receiving radiotherapy

More information: "Clinical impact of selective and non-selective beta blockers on survival in ovarian cancer patients." Jack L. Watkins, Premal H. Thaker, Alpa M. Nick, Lois M. Ramondetta, Sanjeev Kumar, Diana L. Urbauer, Koji Matsuo, Kathryn Squires, Robert L. Coleman, Susan K. Lutgendorf, Pedro T. Ramirez, and Anil K. Sood. Cancer; Published Online: August 24, 2015. DOI: 10.1002/cncr.29392

Related Stories

Lung cancer patients live longer if they use beta-blockers while receiving radiotherapy

January 8, 2013
Patients with non-small-cell lung cancer survive longer if they are taking beta-blockers while receiving radiotherapy, according to a study of 722 patients published in the cancer journal Annals of Oncology today.

Preclinical study identifies 'master' proto-oncogene that regulates ovarian cancer metastasis

January 29, 2013
Scientists at The University of Texas MD Anderson Cancer Center have discovered the signaling pathway whereby a master regulator of cancer cell proteins – known as Src – leads to ovarian cancer progression when exposed ...

Poor survival among colorectal cancer patients tied to biomarker CSN6

August 10, 2015
A protein called CSN6 has been found to be correlated with poor survival among patients with colorectal cancer, according to a study at The University of Texas MD Anderson Cancer Center.

Blood pressure drugs don't protect against colorectal cancer

May 14, 2012
A new study has found that, contrary to current thinking, taking beta blockers that treat high blood pressure does not decrease a person's risk of developing colorectal cancer. Published early online in CANCER, a peer-reviewed ...

Pre-surgery beta blockers, risk of death examined in noncardiac surgery

May 27, 2015
The controversial practice of administering pre-surgery beta-blockers to patients having noncardiac surgery was associated with an increased risk of death in patients with no cardiac risk factors but it was beneficial for ...

Recommended for you

Survivors of childhood Hodgkin lymphoma face high long-term risk of solid cancers

December 17, 2018
New research refines existing evidence that survivors of childhood Hodgkin lymphoma face an elevated risk of developing various types of solid tumors many years later. In addition, certain subgroups of patients have an especially ...

Treatment shown to improve the odds against bone marrow cancer

December 15, 2018
Hope has emerged for patients with a serious type of bone marrow cancer as new research into a therapeutic drug has revealed improved outcomes and survival rates.

Immunotherapy combo not approved for advanced kidney cancer patients on the NHS

December 14, 2018
People with a certain type of advanced kidney cancer will not be able to have a combination of two immunotherapy drugs on the NHS in England.

New drug seeks receptors in sarcoma cells, attacks tumors in animal trials

December 13, 2018
A new compound that targets a receptor within sarcoma cancer cells shrank tumors and hampered their ability to spread in mice and pigs, a study from researchers at the University of Illinois reports.

Surgery unnecessary for many prostate cancer patients

December 13, 2018
Otherwise healthy men with advanced prostate cancer may benefit greatly from surgery, but many with this diagnosis have no need for it. These conclusions were reached by researchers after following a large group of Scandinavian ...

Lethal combination: Drug cocktail turns off the juice to cancer cells

December 12, 2018
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth—this was discovered by researchers from the University of Basel's Biozentrum two years ago. In a follow-up study, ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.